미세잔존질환 검사 시장 : 기술별, 용도별, 최종사용자별, 지역별
Minimal Residual Disease Testing Market, By Technology (Flow Cytometry, Polymerase chain reaction, and Next generation sequencing), By Application, By End User, By Geography
상품코드
:
1482460
리서치사
:
Coherent Market Insights
발행일
:
2024년 04월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
미세잔존질환 검사 시장은 2024년 23억 1,000만 달러로 추정되며 2031년에는 49억 7,000만 달러에 달할 것으로 예상되며 2024년부터 2031년까지 11.6%의 CAGR을 기록할 것으로 예상됩니다.
| 보고서 범위 |
보고서 상세 |
| 기준 연도 |
2023 |
2024년 시장 규모 |
23억 1,000만 달러 |
| 실적 데이터 |
2019-2023년 |
예측 기간 |
2024-2031년 |
| 예측 기간 2024-2031년 CAGR: |
11.60% |
2031년 예측치 |
49억 7,000만 달러 |
그림. 미세잔존질환 검사 시장 점유율(%), 지역별, 2024년
미세잔존질환(MRD) 검사는 1차 치료 후 체내에 남아있을 수 있는 미량의 암세포를 검출하는 검사로, 혈액 전문의와 종양 전문의가 치료 효과를 모니터링하고 환자의 예후를 예측하는 데 중요한 도구입니다. 보다 더 일찍 질병 재발 위험이 높은 환자를 식별할 수 있습니다. MRD를 민감하게 검출하기 위해 다중 파라미터 유세포 분석, 대립 유전자 특이적 올리고뉴클레오티드 정량 PCR, 차세대 염기서열 분석 등 여러 가지 기술이 사용되고 있습니다. 사용되고 있습니다. 다양한 유형의 혈액암에서 MRD 검사의 적용이 확대되고 기술이 향상됨에 따라 향후 몇 년 동안 시장이 크게 성장할 것으로 예상됩니다.
시장 역학:
세계 미세잔존질환 검사 시장은 혈액암 발병률 증가, 치료 모니터링에 MRD 검사 도입 증가, 의사들의 인식 증가에 힘입어 성장하고 있습니다. 그러나 숙련된 전문가 부족, 검사 방법의 고가화, 일부 지역에서의 상환 문제 등이 시장 성장을 저해하고 있습니다. 각 업체들이 민감도가 향상되고 자동화된 플랫폼을 갖춘 다양한 신제품을 출시하고 있으며, 이는 주요 비즈니스 기회로 작용하고 있습니다. 예를 들어, 개인 맞춤형 치료와 액체 생검 기술은 새로운 분야입니다. 기업과 연구기관의 공동 연구도 새로운 지역으로의 시장 확장을 촉진하고 있으며, COVID-19 팬데믹이 의료 자원에 미치는 영향은 도전 과제이지만, 현재 시나리오에서는 원격의료와 재택 검체 채취가 MRD 모니터링의 연속성을 지원하고 있습니다.
본 조사의 주요 특징
- 이 보고서는 2023년을 기준 연도로 하여 예측 기간(2024-2031년)의 시장 규모와 연평균 성장률(CAG%)을 통해 전 세계 미세잔존질환 검사 시장을 상세히 분석합니다.
- 다양한 부문의 잠재적 수익 성장 기회를 확인하고, 이 시장에 대한 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략 등에 대한 주요 인사이트도 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계 미세 잔존 병변 검사 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세계 미세잔존질환 검사 시장은 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 미세잔존질환 검사 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 시장 동향
- 역학
- 최근의 동향
- 인수와 제휴 시나리오
- 자금 조달과 투자
- PEST 분석
- Porters 분석
제4장 세계의 미세잔존질환 검사 시장 : COVID-19 팬데믹의 영향
- 전체적인 영향
- 정부 이니셔티브
- COVID-19에 의한 시장에 대한 영향
제5장 세계의 미세잔존질환 검사 시장 : 기술별, 2019-2031년
- 유세포 분석
- 중합효소 연쇄 반응(PCR)
- 기타
제6장 세계의 미세잔존질환 검사 시장 : 용도별, 2019-2031년
제7장 세계의 미세잔존질환 검사 시장 : 최종사용자별, 2019-2031년
제8장 세계의 미세잔존질환 검사 시장 : 지역별, 2019-2031년
제9장 경쟁 상황
- 기업 개요
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd
- Guardant Health, Inc.
- Adaptive Biotechnologies
- Invitae Corporation
- ASURAGEN, INC.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Sysmex Inostics, Inc.
- Amgen Inc.
- FOUNDATION MEDICINE, INC.
- Sebia
- Myriad Genetics, Inc.
제10장 애널리스트의 견해
- 애널리스트의 견해
- Coherent Opportunity Map
제11장 참고문헌과 조사 방법
ksm
영문 목차
The minimal residual disease testing market is estimated to be valued at USD 2.31 Bn in 2024 and is expected to reach USD 4.97 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031.
| Report Coverage |
Report Details |
| Base Year: |
2023 |
Market Size in 2024: |
US$ 2.31 Bn |
| Historical Data for: |
2019 To 2023 |
Forecast Period: |
2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: |
11.60% |
2031 Value Projection: |
US$ 4.97 Bn |
Figure. Minimal Residual Disease Testing Market Share (%), By Region 2024
Minimal Residual Disease (MRD) testing involves detecting tiny amounts of residual cancer cells that may remain in the body after initial treatment. It is an important tool for both hematologists and oncologists to monitor treatment response and predict outcomes for patients. MRD testing allows physicians to identify those who may be at higher risk of disease relapse earlier than other methods. This helps determine if additional therapies or closer monitoring is needed. Several technologies such as multiparameter flow cytometry, allele-specific oligonucleotide quantitative PCR, and next generation sequencing are used to detect MRD with high sensitivity. With growing applications of MRD testing across different types of blood cancers and improving technologies, the market is expected to witness significant growth in the coming years.
Market Dynamics:
The global minimal residual disease testing market is driven by rising incidence of hematological cancers, increasing adoption of MRD testing in treatment monitoring, and growing awareness among physicians. However, lack of skilled professionals, high index of testing methods, and reimbursement issues in some regions are restraining the market growth. Various new product launches by players with improved sensitivity and automated platforms present key opportunities. For instance, personalized therapy and liquid biopsy techniques are emerging areas. Collaborations between companies and research institutes are also supporting market expansion into new geographies. The effects of the COVID-19 pandemic on healthcare resources is a challenge, though telemedicine and home-based sample collection aid continuity of MRD monitoring in current scenario.
Key Features of the Study:
- This report provides an in-depth analysis of the global minimal residual disease testing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global minimal residual disease testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study includes Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global minimal residual disease testing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global minimal residual disease testing market
Detailed Segmentation-
- Technology:
- Flow Cytometry
- Polymerase chain reaction (PCR)
- Next generation sequencing
- Application:
- Lymphoma
- Solid Tumors
- Others
- End User:
- Hospitals
- Clinics
- Research Laboratories
- Others
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd
- Guardant Health, Inc.
- Adaptive Biotechnologies
- Invitae Corporation
- ASURAGEN, INC.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Sysmex Inostics, Inc.
- Amgen Inc.
- FOUNDATION MEDICINE, INC.
- Sebia
- Myriad Genetics, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Epidemiology
- Recent Developments
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Minimal Residual Disease Testing Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Minimal Residual Disease Testing Market, By Technology, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Flow Cytometry
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Polymerase chain reaction (PCR)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Minimal Residual Disease Testing Market, By Application, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Lymphoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Solid Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Minimal Residual Disease Testing Market, By End User, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Research Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Minimal Residual Disease Testing Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2031
- Regional Trends
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Bio-Rad Laboratories, Inc.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Guardant Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Adaptive Biotechnologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Invitae Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ASURAGEN, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Invivoscribe, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Laboratory Corporation of America Holdings
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Natera, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sysmex Inostics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- FOUNDATION MEDICINE, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sebia
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Myriad Genetics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
관련자료
